Vanguard Capital Management
SKYE icon

Vanguard Capital Management’s Skye Bioscience SKYE Stock Holding History

Vanguard Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$529K Sell
763,882
-575
-0.1% -$452 ﹤0.01% 3704
2026
Q1 		$470K Buy
+764,457
New +$623K ﹤0.01% 3681

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's SKYE Position: Q2 2026 in Review

Vanguard Capital Management reduced its Skye Bioscience (SKYE) stake by 0.08% in Q2 2026, selling an estimated $452 and leaving 763,882 shares worth $529K. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

Vanguard Capital Management first reported a position in SKYE in Q1 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Vanguard Capital Management held 763,882 shares of Skye Bioscience worth $529K as of Q2 2026.
  • Vanguard Capital Management sold 575 Skye Bioscience shares in Q2 2026, an estimated $452.
  • Skye Bioscience made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3704 holding.
  • Vanguard Capital Management first reported a position in Skye Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.